The warning came a day after the World Health Organization said the scale of the epidemic had been vastly underestimated and that "extraordinary measures" were needed to contain the killer disease.
The UN health agency said the death toll from the worst outbreak of Ebola in four decades had now climbed to 1,069 in the four afflicted West African countries -- Guinea, Liberia, Nigeria and Sierra Leone.
"It is deteriorating faster, and moving faster, than we can respond to," Joanne Liu, the chief of Doctors without Borders, known by its French acronym MSF, told reporters in Geneva.
"It is like wartime," she said a day after returning from the region. "I don't think we should focus on numbers. To really get a reality check, we're not talking in terms of weeks, but months" to control the epidemic."
WHO said yesterday it was coordinating "a massive scaling up of the international response" to the epidemic.
"Staff at the outbreak sites see evidence that the numbers of reported cases and deaths vastly underestimate the magnitude of the outbreak," it said.
The epidemic erupted in the forested zone straddling the borders of Guinea, Sierra Leone and Liberia earlier this year, and later spread to Nigeria.
Liu said while Guinea was the initial epicentre of the disease, the pace there has slowed, with fears now focused on the other countries.
"If we don't stabilise Liberia, we'll never stabilise the region," Liu said.
Concerns have also centred on the Nigerian cases, which are in Lagos, sub-Saharan Africa's largest city.
"Right now we have no past experience of Ebola within an urban setting," said Liu.
As countries around the world stepped up measures to contain the disease, the International Olympics Committee said athletes from Ebola-hit countries had been barred from competing in pool events and combat sports at the Youth Olympics opening in China tomorrow.
No cure or vaccine is currently available for Ebola, with the WHO authorising the use of largely untested treatments in efforts to combat the disease.
Hard-hit nations are awaiting consignments of up to 1,000 doses of the barely tested drug ZMapp from the United States, which has raised hopes of saving hundreds.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
